Shots:
- Amgen has reported the global P-III (VESALIUS-CV) trial findings assessing Repatha vs PBO, both in addition to optimized lipid-lowering therapy in adults (n >12,000) at high CV risk without prior heart attack or stroke
- At an mFU of 4.5yrs., the trial met its co-1EPs of time to first occurrence of composite of coronary heart disease (CHD) death, heart attack, or ischemic stroke, & time to first occurrence of composite of CHD death, heart attack, stroke, or ischemic stroke, or any ischemia-driven arterial revascularization; data to be presented at AHA’25 & published in a journal
- Repatha is a human mAb that binds to PCSK9, preventing it from degrading LDL receptors (LDLR), thereby allowing more receptors to recycle to the liver & reduce LDL from the blood
Ref: Amgen | Image: Amgen | Press Release
Related News:- AstraZeneca and Amgen Report the CHMP’s Positive Opinion of Tezspire (Tezepelumab) for CRSwNP
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
